Tuesday, 18 January 2022

 

 

LATEST NEWS Mission Youth initiative enables many Kishtwar youth to earn livelihood with dignity DC Rajouri flags off 4 Advance Life Saving Ambulances DC Kupwara for implementation of Covid norms DC Ganderbal visits Sonamarg, takes stock of availability of essential services and other facilities “Awaam Ki Awaaz” : Lt Governor enlists breakthrough steps and initiatives for economic growth and equitable development of J&K ECI Reschedules Punjab Assembly Polls To February 20, 2022, Informs CEO Punjab Bandaru Dattatraya flagged off two trucks containing 4000 hygiene kits prepared by the Indian Red Cross Society Two time MLA Luv Kumar Goldy joins Punjab Lok Congress State Government proposes outlay of Rs. 12638 crore for budget 2022-23 Governor asks experts to provide holistic solution to make Himachal a role model for landslide risk resilient state If given an opportunity, it will be an honour: Jasprit Bumrah on captaincy Sushil Pandey talks about his working experience in 'Human' Rahul Bansal goes bad, turns villain in cop drama 'Bhaukaal 2' Nearly 3 cr Covid vaccines administered in Delhi: Satyendar Jain How Akshita Mudgal wore a 28-kg lehenga for wedding sequence in 'Iss Mod Se Jaate Hain' I'd always love to be part of Marathi showbiz : Aditya Deshmukh Virat Kohli told us after Cape Town Test that he will be stepping down from captaincy: Jasprit Bumrah Equities continue gains, settle marginally up CHJU Submitted memorandum to Power Minister Ranjit Singh & Transport Minister Mool Chand Sharma regarding demands of the journalists No. 1 Ashleigh Barty begins quest for first Australian Open title with easy win Delhi govt aims to bring 2,000 electric buses in coming years: Arvind Kejriwal

 

Zydus launches Ujvira, breakthrough in breast cancer treatment

Health, Zydus Cadila, Trastuzumab Emtansine,  Antibody Drug Conjugate, ADC, Ujvira, Sharvil Patel, Breast Cancer, Cancer, HER2 positive Breast Cancer

Web Admin

Web Admin

5 Dariya News

New Delhi , 24 May 2021

Zydus Cadila launched Trastuzumab Emtansine, the first Antibody Drug Conjugate (ADC) biosimilar and a highly effective drug for treating both Early and Advanced HER2 positive Breast Cancer, under the brand name 'Ujvira'.HER2 positive Breast Cancer is considered an aggressive form and constitutes 20 to 25 per cent of all Breast Cancers. In a step that can significantly reduce treatment cost by almost 80 per cent, the drug is being offered at Rs 32,495 for a 100 mg vial.The current MRP of existing Trastuzumab Emtansine drug is Rs 1,59,225 for 100 mg vial. Ujvira will be available in two strengths, 100 mg and 160 mg.Speaking on this milestone, Sharvil Patel, Managing Director, Cadila Healthcare Limited said, "The launch of Ujvira reinforces the innovation capabilities that India has to be able to create complex therapies like ADCs and Zydus' ongoing commitment to offer breakthroughs backed by science and innovation. This research breakthrough enables access to a critical drug for patients who are undergoing therapy for Breast Cancer. We hope that with this innovation, patients will be able to adhere to the treatment and stand to benefit from the advanced technology without worrying about the cost of the treatment."Trastuzumab Emtansine ADC biosimilar is developmental breakthrough due to its complexity in manufacturing and similarity assays.This drug is made by combining Trastuzumab and a cytotoxic compound Emtansine (DM1) with the help of a stable linker by a process called Antibody Drug Conjugation. Due to this technology the targeted delivery of the cytotoxic agent is enabled and the other toxicities on body are reduced. Ujvira is backed up with rigorous drug development programme.Patients already treated with Trastuzumab may still have the disease and would require this therapy as the next step. The high cost of therapy is a barrier to availing this therapy and Ujvira bridges this need.With more than 2.1 lakh new cases in 2020, Breast Cancer is the leading cancer in females in India and the risk increases with age. It is estimated that 1 in 29 women in India has a risk of developing Breast Cancer in her lifetime. Though rare, the incidence of HER2 Breast Cancer is also found in men. Other risk factors such as obesity, family history, genetics, alcohol, smoking, hormonal imbalance and improper diet have been identified as the contributing factors towards an increased incidence of Breast Cancer.

 

Tags: Health , Zydus Cadila , Trastuzumab Emtansine , Antibody Drug Conjugate , ADC , Ujvira , Sharvil Patel , Breast Cancer , Cancer , HER2 positive Breast Cancer

 

 

related news

 

 

 

Photo Gallery

 

 

Video Gallery

 

 

5 Dariya News RNI Code: PUNMUL/2011/49000
© 2011-2022 | 5 Dariya News | All Rights Reserved
Powered by: CDS PVT LTD